Efficacy and Safety of Janagliflozin as Add-on Therapy to Metformin in Chinese Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Alone: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Trial.
Diabetes, Obesity and Metabolism(2022)
Abstract
Janagliflozin 25 mg or 50 mg once-daily added to metformin therapy significantly improved glycemic control, reduced body weight and SBP, improved HDL-C and insulin sensitivity, and was generally well-tolerated by Chinese T2DM patients who had poor glycemic control with metformin monotherapy. This article is protected by copyright. All rights reserved.
MoreTranslated text
Key words
add-on therapy,janagliflozin,metformin,renal sodium-glucose cotransporter-2 inhibitor,type 2 diabetes mellitus
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined